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[Cp*Ru]-Catalyzed Selective Coupling/Hydrogenation 
I. Labed.b A. Labed.b Y. Sun.a F. Jiang.a M. Achard.a* S. Dérien.a Z. Kabouche.b and C. Bruneaua  
Accesses to 3,4- and 3,5-disubstituted piperidine derivatives have been achieved through [Cp*Ru]-catalyzed 
intermolecular coupling of allylic alcohols and propargylic amides. Tandem transformation was also possible via 








In regards to their applications in agrochemicals and pharmaceuticals, functionalized piperidine derivatives 
represent an important class of alkaloids and new methodologies for the preparation of substituted piperidine 
derivatives have attracted the attention of many researchers. 1,2 Traditional approaches to access 
polyfunctionalized piperidines usually involve alkylation, arylation of piperidone derivatives, hydrogenation of 
substituted pyridine or cycloadditions. 3-6 Multicomponent cascade transformations constitute new 
straightforward protocols for the syntheses of polysubstituted piperidines.6 Recently, direct functionalization of 
piperidines have emerged as excellent alternatives to the aforementioned methodologies. Among the latter, 
neutral redox processes involving the formation of transient azomethine ylides from aldehydes and amines have 
been efficiently used for the preparation of 2- and 2,3-(di)substituted piperidines. 2f,7 The preparation of cyclic 
enamines or enamides containing reactive carbons at the α and β positions towards nucleophile and electrophile, 
respectively constitute another important approach for the preparation of 2,3-disubstituted piperidines.8 On the 
other hand, the use of transition metal complexes has gained increasing importance due to their ability to 
construct valuable N-heterocycles. Hydrogen borrowing or hydrogen autotransfer processes have been efficiently 
applied for the preparation of piperidine derivatives from primary amines and 1,5-pentanediols. 2a,b,e,9 This 
methodology also allowed the postfunctionalization of cyclic amines at 2- or 3-position through metal-catalyzed 
redox processes.10 Cross Dehydrogenative Coupling (CDC) involving the formation of electrophilic iminium ion via 
oxidative processes has found broad application in α functionalization of amines.11 Metal-catalyzed C-H 
functionalization of cyclic enamide derivatives proved to be a powerful tool to synthesize substituted 
piperidines.12 Direct functionalization of saturated piperidines represents another interesting approach for either 
α- or β-substituted piperidines. 13 Among the polysubstituted piperidines, 4-phenylpiperidine 
 
Figure 1 Representative examples of 4-phenylpiperidines 
 derivatives such as paroxetine, femoxetine, picenadol, pethidine, terikalant, haloperidol and related structures 
have found broad applications as antidepressant, antipsychotic and other related biological properties (Figure 1). 
4b,14-18 However, straightforward accesses to 4-phenylpiperidine derivatives through transition metal-catalysis 
remain scarce.19 
Recently, we reported that [Cp*Ru]-based catalysts can be judiciously employed in regioselective oxidative 
coupling between propargylic amines and aliphatic allylic alcohols to offer straightforward accesses to 
dehydropiperidine derivatives.20 Taking advantage of this methodology by substrate scope broadening, we now 
disclose that {[Ru(Cp*)(CH3CN)3]PF6}-catalyzed the chemoselective semi-hydrogenation of the resulting 
homodienes allowing the development of the tandem transformation. 
Results and discussion 
Various cyclic enamides 3f-3j were previously prepared from the corresponding linear aliphatic allylic alcohols 
with propargylic amides 2 through ruthenium-catalyzed coupling.20 However, during the coupling between 
cinnamyl alcohol 1a and propargylic sulphonamide 2a in the presence of catalytic amount of 
{[Ru(Cp*)(CH3CN)3]PF6}, results demonstrate the crucial importance of the substituents on the allylic alcohol on 
the reaction efficiency and side isomerization (Scheme 1).  
Table 1 . Synthesis of 3-methylidene-4-phenyl disubstituted enamide 3a a 
 
Entry Ratio 1/2 T (°C) Conversionb 
1 5/1 80 35 
2 2.5/1 80 39 
3 2/1 80 41 
4 1.5/1 80 48 
5 1/1 80 54 
6 1/2 80 42 
7 1.2/1 60 0 
8 1.2/1 100 72 
9 1.2/1 125 58 
10c 1.2/1 100 95(74) 
a All reactions were carried out in THF for 15 h under an inert atmosphere of argon with 2a/[Ru] in 1/0.05 molar 
ratio. b Conversion determined by GC. Number in parentheses is isolated yield after purification. c reactions were 
carried out in THF for 15 h under an inert atmosphere of argon with 2a/[Ru] in 1/0.08 molar ratio. 
Our previously reported procedure involving slow addition of the protected propargylic amine 2a and 2b was 
found to be unsuitable highlighting faster isomerization of 1a to 3-phenylpropanal than the expected coupling (3f-
j, Scheme 1).20 Therefore, after an initial screening of solvents, THF and DCE were found to be suitable for the 
 transformation. The temperature exerted a strong influence on conversion and the formation of 3a was not 
observed with reaction temperature below 60 °C (entry 7). Increasing the amount of alcohol 1a highlighted the 
side formation of undesired hemiaminal ethers presumably resulting from the nucleophilic attack of the alcohol 
on the cyclic enamide and side formation of aldehyde arising from the isomerisation of the allylic alcohol 1a 
(entries 1 to 4). A best 1.2:1 ratio of the alcohol limited these side reactions. Performing the reaction in sealed 
tube at 100 °C afforded up to 72% conversion (entry 8). It is noteworthy that at higher reaction temperatures 
above 120 °C, noticeable amount of p-toluene sulphonamide resulting from the depropargylation of 2a was 
detected (entry 9). Finally, with the best reaction conditions, the use of higher catalyst loading improved the 
transformation affording almost complete conversion and the formation of 3a in 74% isolated yield after a rapid 
purification by short column chromatography over neutralized silica gel to minimize degradation (entry 10). The 
importance of the nitrogen protecting group was next investigated with allylic alcohol 1a. Under our optimized 
reaction conditions, no reaction took place in the presence of propargylic aniline 2d presumably due to the 
stronger coordination of the nitrogen atom to the ruthenium center. To our delight, amide 2c, sulphonamide 2a 
and carbamate 2b functionalities were found to be suitable leading to the formation of cyclic products 3a-c in 70-
87% range yields (Scheme 1). Similarly, 4-nitrocinnamyl alcohol 1b reacts cleanly with 2a affording 3d in 65% 
isolated yield. In contrast, under similar reaction conditions, 2-substituted allylic alcohols such as methallyl 
alcohol 1c was found to be less reactive and required a modified procedure involving large excess of the methallyl 
alcohol 1c (5 equiv.) to observe the formation of the cyclic enamide product 3e. In these cases, the lower 
reactivity of the resulting cyclic enamide 
 
Scheme 1 Access to 3,4- and 3,5-disubstituted enamides 3. 
diminished side hemiaminal ether formation in THF yielding from 2a, the 3,5-disubsituted product 3e in 84% 
(Scheme 1). Taken together these results demonstrated that the steric hindrance of the allylic alcohols has a 
strong impact on the reaction efficiency and linear aliphatic alcohols were found to be more reactive and less 
sensitive to side reactions in such processes (compounds 3f-3j in scheme 1). As previously observed with similar 
structures, it is noteworthy that performing the reaction in methanol with propargylic amines 2a and 2b in the 
presence of cinnamyl alcohol 1a, cleanly afforded the more stable hemiaminal ethers 4a and 4b with a 9:1 
diastereoisomeric ratio (Scheme 2).20,21 
 
Scheme 2 . Preparation of hemiaminal ethers 4. 
 Rationalization of these results was next undertaken. Upon non reductive elimination/addition, the propargylic 
amides 2 and allylic alcohols 1 react with the cationic [Cp*Ru]+ fragment to form two key intermediates I and II in 
equilibrium whereas, the presence of more nucleophilic amine such as propargylic aniline 2d inhibited the 
formation of these proposed key intermediates presumably due to the coordination of the nitrogen atom to the 
ruthenium centre leading to intermediates III (Figure 2). The coordination of the oxygen atom on the cationic 
ruthenium fragment thus facilitating the introduction of the allylic alcohol in I could also explain the lower activity 
of the neutral [Cp*Ru(COD)Cl] in such transformations.20 Oxidative cyclization of II gave the cationic 
ruthenacyclopentene IV. The steric interaction between the R3 group and the Cp* ligand thus reducing the 
cyclization rate might account for the lower reactivity of methallyl alcohol 1c during this process.22 Then, 
intermediate IV undergoes β-H elimination with the former allylic proton and the ruthenium affording the hydrido 
ruthenium(IV) V. Reductive elimination from V gives back the active cationic [Cp*Ru]+ moiety and generates the 
intermediate aminoaldehyde VI , which releases the enamides 3 after intramolecular condensation with 
elimination of water. 
 
 
Figure 2 Postulated mechanism accounting on products 3. 
Using methanol as solvent, the presence of an excess of cinnamyl alcohol 1a, led to the side formation of (3,3-
dimethoxypropyl)benzene 5. Interestingly, we found that the complete formation of this acetal was only possible 
when {[Ru(Cp*)(CH3CN)3]PF6} along with catalytic amount of 2a were used as catalytic system for this 
isomerisation-acetalisation sequence (Scheme 3). These last results tend to demonstrate that the generated 
electrophilic ruthenium species promoted acetal formation and could also play a role during the transformation 
of intermediate VI to enamide 3.  
 
Scheme 3 . [Ru]-catalyzed acetal formation from allylic alcohols. 
Considering that products 3 and 4 feature a methylene group, we next investigated the postfunctionalization of 
these products in hydroboration-oxidation sequence to access 3-hydroxymethylpiperidine derivatives. The use of 
Thexylborane with 3a didn’t afford the expected product.23 To our delight, performing similar reaction with 
BH3:DMS made possible the formation of the expected compound along with noticeable amount of side products 
arising from the side reaction of the endo cyclic insaturation. Finally, replacing 3a by its corresponding hemiaminal 
ether 4a afforded 5a in a 75:19:6 stereoisomeric mixture and 76% isolated yield (Scheme 4). 
  
Scheme 4 . Hydroboration-Oxidation of 4a. 
The beneficial presence of C-Me bonds in alkaloids and heterocycles recently highlighted as the “magic methyl 
effect” has attracted a lot of interest and can contribute to an increase of their biological activities. 24 The 
methylene moiety in products 3 could be therefore selectively reduced to a methyl group keeping intact the endo 
cyclic insaturation for further posfunctionalization. Selective hydrogenation of dienes into alkene in the presence 
of [Cp*Ru]-based catalyst have been reported by Drießen-Hölscher. 25 During this study, it was observed that the 
use of organophosphorous ligand such as tris(hydroxypropyl)phosphane favoured complete hydrogenation of the 
diene into its corresponding alkane. We investigated the semi-hydrogenation of 3a using {[Ru(Cp*)(CH3CN)3]PF6} 
as precatalyst to further perform the tandem coupling/hydrogenation transformation.26 Initial attempt to 
hydrogenate 3a without additives demonstrated that semi hydrogenation was possible at 120 °C under 45 bars of 
H2 but side isomerisation of the exo-insaturation occurred to afford the conjugated diene (Table 2, entry 1). 
Table 2 . [Ru(Cp*)]-catalyzed semi hydrogenation of enamide 3a a 
 










1 45 120 None 75 55/35/10 70/30 
2 45 120 A (5%) 99(75) 100/0/0 70/30 
3 45 120 B (5%) 99(70) 80/0/20 80/20 
4 35 110 A (5%) 99 100/0/0 70/30 
5 25 120 A (5%) 97 95/5/0 65/35 
6 60 90 A (5%) 80 100/0/0 75/25 
7 65 110 A (5%) 99 100/0/0 75/25 
8 65 110 B (5%) 99 90/1/9 80/20 
9 50 110 C (5%) 93 84/2/14 80/20 
a All reactions were carried out in a 20 mL reactor using THF for 15h with 3a/[Ru]/additive in 1/0.05/0.05 molar 
ratio. b Number in parentheses is isolated yield of 7a after purification. c ratio 7/8/9 were determined by GC. d 
cis/trans ratio was determined by GC and 1H NMR.  
 Recently, Fehr and co-workers at Firmenich showed the beneficial role of Brönsted acid as additive to prevent 
isomerisation during hydrogenation of dienes for the synthesis of Santalol. 27 Thus, a set of sulfonic acid 
derivatives was evaluated for this transformation (Figure 3). Gratifyingly, the use of phosphine-sulfonic acids (5 
mol%) such as A and B led to complete conversion and suppress the side isomerisation affording 7a in up to 70-
75% isolated yield and 70:30-80:20 cis:trans ratios, respectively (entries 2 and 3). Best diastereoselectivity was 
obtained with additive B (entries 3 and 8). However, in these cases noticeable amount of fully reduced products 
9a were also observed demonstrating that A led to the best chemoselectivity. Importantly, lower or higher 
amount of the acidic additive reduced the catalytic activity. The structure of the major diastereoisomer was 
unequivocally determined by NMR analyses where the high-field ethylenic protons appeared as a set of two 
doublet of doublet at 4.77 and 4.68 ppm with a 5.0 and 2.3 Hz coupling constants with the allylic proton 
corresponding to the cis and trans isomers, respectively (Figure 4). Further confirmation  
 
Figure 3 . Additives employed during hydrogenation. 
was obtained by selective crystallization of the cis isomer 7a (Figure 4).28 Interestingly, no degradation occurred 
during the purification of the enamide 7a demonstrating its higher stability compared to the homodiene 3a. 
Performing the reactions at 110-120 °C in the presence of {[Ru(Cp*)(CH3CN)3]PF6} and A showed that under lower 
H2 pressure although full conversions were observed, slight decrease of the cis:trans ratio of 7a were also noticed 
(entry 4 compared to 7 and entry 2 compared to 5). The conversion was affected by reaction temperature and 
only 80% was reached at 90 °C under 60 bar of molecular hydrogen (entry 6).  
 
 
 Figure 4 . X-ray structure of the semi reduced cis-cyclic enamide 7a and representative ethylenic proton signals of 
the two diastereoisomers. 
At this stage, we wondered if the diastereoselectivities obtained in the presence of A and B arose from the 
coordination of the phosphine or from simple sterical or acidic outcomes of the additive. Therefore, the use of 
benzene sulfonic acid C, as additive highlighted similar diastereoselectivity leading to 80:20 cis:trans ratio but with 
uncompleted conversion, suggesting that with these two phosphine ligands no binding to metal center of the 
phosphorus atom seems to occur during the hydrogenation in THF as solvent (entry 9).  
Although a detailed mechanism for the ruthenium-catalysed alkene hydrogenation29 is yet to be established, 
alkene hydrogenation could occur through consecutive insertion of the coordinated alkene followed by reductive 
elimination on the cationic hydrido/hydrogen species [Ru(Cp*)H2]+.30-31 A ionic process involving protonation by 
the acidic [Ru(Cp*)(η2-H2)]+ followed by reduction with side generated neutral [Ru(Cp*)H] cannot totally be 
excluded.32 It should be noted that when the reactions were carried out in the presence of arene ruthenium(II) 
complexes featuring similar ligands complete reduction of the homodienes were selectively obtained which tend 
to suggest that the Cp* ligand remained intact under these reaction conditions.20 More important is the influence 
of the acidic additives on preventing the isomerization processes and toward the reaction efficiency. Recently, 
Grotjahn and coworkers demonstrated that cationic ruthenium(II) species bearing bifunctional ligand play an 
important role in isomerization through the possible intervention of allylic ruthenium species where the basic 
nitrogen of the imidazole facilitates the η3-allylic formation via reversible deprotonotation.33 In contrast, the 
necessity of acidic additives A-B could prevent the formation of such allylic species via prior protonation/oxidative 
addition mechanism. On the other hand, Nozaki demonstrated that during hydroformylation of alkenes, 
[Ru(Cp*)H] species efficiently catalysed the isomerization through reversible insertion.34 Therefore acidic 
additives might also play a role on the catalytic activity and prevent isomerization by regenerating [Ru(Cp*)H2]+ 
from neutral [Ru(Cp*)H] and dinuclear (μ-H) monocationic ruthenium(II) species.32-35-37 
With these results in hand, we investigated the possibility to perform the tandem process with additive B which 
afforded better diastereoselectivities. After several attempts, we found that the acidic additive must be added 
only at the second stage to allow the coupling of propargylic amide 2a with cinnamyl alcohol 1a. Importantly, 
lower amount of the sulfonic acid B was necessary demonstrating partial degradation of the catalyst during the 
initial coupling and required optimization of the reaction conditions to overcome this issue. Thus, initial 
optimization afforded 7a in 52% isolated yield and 75/25 diastereoisomeric ratio (Scheme 5). 
 
Scheme 5 . Tandem Coupling/Hydrogenation. 
Conclusions 
In conclusion, we demonstrated that the selective oxidative coupling between allylic alcohols and propargylic 
amines can be extended to cinnamyl alcohol derivatives and 2-substituted allylic alcohols. This methodology 
allows the access to 3,4- and 3,5-disubstituted enamides as valuable scaffolds for the preparation of 3-
methylpiperidine derivatives through selective [Ru(Cp*)]-catalyzed alkene hydrogenation. 
Experimental 
General considerations 
 All reactions were carried out under an inert atmosphere with standard Schlenk techniques, unless otherwise 
mentioned. THF was purified by solvent purification system equipped with a series of activated filter columns. 
Benzene sulfonic acid was purchased from commercial sources and used as received. ligands A and B were 
prepared according literature protocols.38 Propargylic amines 2 were prepared according to reported procedures. 
39 Compounds 3f-j were already reported in reference 20. Proton magnetic resonance (1H NMR) spectra were 
recorded on Bruker 400 MHz spectrometer and carbon magnetic resonance (13C NMR) spectra were performed at 
100 MHz. Chemical shifts (δ) are reported in parts per million relative to residual solvent signals (CD2Cl2 5.32 and 
53.84; C6D6 7.15 and 128.02, CD3OD 5.84 and 49.05). Coupling constants are reported in Hertz. 1H NMR 
assignment abbreviations are the following: singlet (s), doublet (d), triplet (t), quartet (q), pentet (p), broad singlet 
(bs), doublet of doublets (dd), doublet of triplets (dt), and multiplet (m). All reagents were weighed and handled 
in air, and refilled with an inert atmosphere of argon at room temperature to prevent oxidation. HRMS were 
recorded on a Waters Q-Tof 2 with an ESI source. 
General Procedure for preparation of the enamides 3-4  
To a dried pressure tube under an inert atmosphere, propargylic amine 2 (0.239 mmol, 1eq), allylic alcohol 
substrate 1 (1.2 eq) were dissolved in THF or methanol (0.5 to 1 mL) followed by the addition of 
{[Ru(Cp*)(CH3CN)3]PF6} (5 mol% (MeOH) or 8 mol% (THF)). The resulting solution was stirred at 100°C for 15h. 
Reaction completion was monitored using GC, GC-MS and TLC techniques. After concentration in vacuo, the crude 
mixture was purified by short column chromatography over dried deactivated silica gel. 
3-methylene-4-phenyl-1-tosyl-1,2,3,4-tetrahydropyridine 3a 
Prepared from N-tosyl propargylamine 2a (50 mg, 0.239 mmol) and cinnamyl alcohol 1a (0,288 mmol, 1.2 eq) in 
THF (0,5 mL). Chromatography on silica gel using PE/Et2O (80:20) as eluent afforded compound 3a as yellow oil, 
58 mg (74%), 1H  NMR (400 MHz, CD2Cl2) δ 7.69 (d, J= 8.1 Hz, 2H), 7.36 (d, J= 8.1 Hz, 2H), 7.20-7.15 (m, 3H), 6.98-
6.95 (m, 2H), 6.84 (d, J= 8.0 Hz, 1H), 5.10 (dd, J= 4.4, 8.0 Hz, 1H), 4.90 (bs, 1H), 4.81 (bs, 1H), 3.96 (d, J= 12.9 Hz, 
1H), 3.93 (bs, 1H), 3.67 (d, J= 12.9 Hz, 1H), 2.45 (s, 3H) ; 13C NMR (100 MHz, CD2Cl2) δ 144.6, 142.8, 141.4, 134.8, 
130.1, 128.6, 128.2, 127.7, 127.0, 126.5, 113.7, 110.7, 48.3, 45.4, 21.7 ; HRMS calcd for C19H19NO2NaS [M+Na]+ 
348.10342 found 348.1035 (0 ppm). 
Tert-butyl 3-methylene-4-phenyl-3,4-dihydropyridine-1(2H)-carboxylate 3b 
Prepared from N-Boc propargylamine 2b (50 mg, 0.322 mmol) and cinnamyl alcohol 1a (1.2 eq, 0,376 mmol) in 
THF (0,7 mL). Chromatography on silica gel using PE/Et2O (70:30) as eluent afforded compound 3b as colourless 
oil as a mixture of isomers in a 3:2 ratio due to the Boc protecting group, (76 mg, 87%) 1H NMR (400 MHz, CD2Cl2) 
δ 7.32-7.22 (m, 5H), 7.09-6.97 (2bs, 1H), 5.06-4.88 (m, 3H), 4.20-4.11 (m, 1H), 4.08 (d, J= 3.6 Hz, 1H), 3.86 (d, J= 
13.6 Hz, 1H), 1.50 (bs, 9H) ; 13C NMR (100 MHz, CD2Cl2) δ 152.5 (I1, C=O) 152.1 (I2, C=O), 148.0 , 147.8, 143.6, 
143.5, 128.7, 128.3, 126.9, 125.1, 112.6 (I1, =CH2), 112.5 (I2, =CH2), 106.4, 106.1, 81.25, 47.4, 46.3, 45.8, 45.7, 
28.4 ; GC-MS m/z (%): 271 (M+, 1%), 215, 200, 170, 142. 
(3-methylene-4-phenyl-3,4-dihydropyridin-1(2H)-yl)(phenyl)methanone 3c 
Prepared from N-(prop-2-ynyl)benzamide 2c (50 mg, 0.314 mmol) and cinnamyl alcohol 1a (1.2 eq, 0,41 mmol) in 
THF (0,6 mL). Chromatography on silica gel using PE/Et2O (70:30) as eluent afforded compound 3c as colourless 
oil, 61 mg (70%) 1H NMR (400 MHz, CD2Cl2) δ 7.52-7.43 (m, 5H), 7.35-7.23 (m, 5H), 6.73-6.70 (m, 1H), 5.16-5.14 
(m, 1H), 5.00-4.93 (m, 2H), 4.48 (d, J= 13.4 Hz, 1H), 4.18-4.16 (m, 1H), 4.11 (d, J= 13.4 Hz, 1H) ; 13C NMR (100 MHz, 
CD3OD) δ 171.0, 144.0, 143.7, 135.9, 131.9, 129.8, 129.6, 129.2, 129.1, 128.8, 127.9, 114.0, 111.3, 47.3, 47.0 ; 
HRMS calcd. for C19H17NONa [M+Na]+ 298.12078 found 298.1207 (0 ppm). 
 3-methylene-4-(4-nitrophenyl)-1-tosyl-1,2,3,4-tetrahydropyridine 3d 
Prepared from N-tosyl propargylamine 2a (50 mg, 0.239 mmol) and 4-nitrocinnamyl alcohol 1a (1.2 eq, 0,286 
mmol) in THF (0,5 mL). Chromatography on silica gel using PE/Et2O (50:50) as eluent afforded compound 3d as 
colourless oil, 57 mg (65%) 1H NMR (400 MHz, C6D6) δ 7.65 (d, J= 8.6 Hz, 2H), 7.58 (d, J= 8.2 Hz, 2H), 6.90, (dd, J= 
1.6, 8.1 Hz, 1H), 6.72 (d, J= 8.2 Hz, 2H), 6.42 (d, J= 8.6 Hz, 2H), 4.49 (bs, 1H), 4.47 (dd, J= 4.4, 8.1 Hz, 1H), 4.30 (bs, 
1H), 3.80 (d, J= 13.0 Hz, 1H), 3.50 (d, J= 13.0 Hz, 1H), 3.30 (d, J= 3.5 Hz, 1H), 1.88 (s, 3H) ; 13C NMR (100 MHz, C6D6) 
δ 149.3, 147.1, 143.8, 140.0, 135.4, 129.7, 128.6, 128.1, 127.6, 123.4, 114.0, 107.9, 47.9, 44.7, 21.0 ; HRMS calcd. 
for C19H18N2NaO4S [M+Na]+ 393.0885, found 393.0884 (0 ppm). 
5-methyl-3-methylene-1-tosyl-1,2,3,4-tetrahydropyridine 3e 
Prepared from N-tosyl propargylamine 2a (50 mg, 0.239 mmol) and 2-methylprop-2-en-1-ol 1c (5 eq, 1.19 mmol) 
in THF (1 mL). Chromatography on silica gel using DCM/PE/Et2O (80:10:10) as eluent afforded compound 3e as 
colourless oil (53 mg, 84%); 1H NMR (400 MHz, CD3OD) δ 7.64 (d, J= 8.1 Hz, 2H), 7.35 (d, J= 8.1 Hz, 2H), 6.40 (bs, 
1H), 4.82 (s, 1H), 4.81 (s, 1H), 3.83 (s, 2H), 2.56 (s, 2H), 2.41 (s, 3H), 1.67 (s, 3H); 13C NMR (100 MHz, CD3OD) δ 
145.2, 138.5, 136.2, 130.6, 128.5, 120.8, 119.8, 112.5, 50.5, 35.6, 21.4, 20.3; HRMS calcd for C14H17NO2NaS 
[M+Na]+ 286.0877 found 286.0876 (1 ppm). 
2-methoxy-5-methylene-4-phenyl-1-tosylpiperidine 4a 
Prepared from N-tosyl propargylamine 2a (50 mg, 0.239 mmol) and cinnamyl alcohol 1a (1.2 eq, 0,288 mmol) in 
MeOH (0,5 mL). Chromatography on silica gel using PE/Et2O (70:30) as eluent afforded compound 4a as yellow oil 
in a 93/7 diastereoisomeric mixture (70 mg, 82%), 1H NMR (400 MHz, C6D6) δ 7.74 (d, J= 8.2 Hz, 2H), 7.06-6.98 (m, 
3H), 6.79-6.77 (m, 4H), 5.26 (t, J= 0.5 Hz, 1H), 4.59 (bs, 1H), 4.27 (d, J= 14.3 Hz, 1H), 4.10 (bs, 1H), 3.84 (d, J= 14.3 
Hz, 1H), 3.74-3.70 (m, 1H), 3.23 (s, 3H), 1.89 (s, 3H), 1.84 (ddd, J= 2.0, 4.1, 13.2 Hz, 1H), 1.59 (dt, J= 3.2, 13.1 Hz, 
1H); 13C NMR (100 MHz, C6D6) δ 134.8, 142.8, 141.3, 138.9, 129.5, 128.8, 128.6, 127.8, 127.0, 111.8, 84.8, 55.0, 
47.6, 42.0, 36.7, 21.0; HRMS calcd for C20H23NO3NaS [M+Na]+ 380.12964 found 380.1289 (1 ppm). 
Tert-butyl 2-methoxy-5-methylene-4-phenylpiperidine-1-carboxylate 4b 
Prepared from N-Boc propargylamine 2b (50 mg, 0.322 mmol) and cinnamyl alcohol 1a (1.2 eq, 0,387 mmol) in 
MeOH (0,6 mL). Chromatography on silica gel using PE/Et2O (70:30) as eluent afforded compound 4b as colourless 
oil, 62 mg (64%), as two isomers due to the Boc protecting group (63/37 ratio) in a 90/10 diastereoisomeric ratio. 
1H NMR (400 MHz, CD2Cl2) δ 7.32 (t, J= 7.2 Hz, 2H), 7.24 (td, J= 7.2, 1.1 Hz, 1H), 7.19 (brd, J= 7.2 Hz, 2H), 5.55 (bs, 
0.4 H), 5.44 (bs, 0.6H), 4.93-4.87 (m, 1H), 4.47 (d, J= 14.0 Hz, 0.6H), 4.35-4.32 (m, 0.4H), 4.13 (bs, 1H), 3.80 (dd, J= 
14.0, 4.0 Hz, 1H), 3.74 (d, J= 14.0 Hz, 0.4H), 3.64 (d, J= 14.0 Hz, 0.6H), 3.30 (s, 2.6H), 3.28 (s, 0.4H), 1.48 (s, 9H) ; 13C 
NMR (100 MHz, CD2Cl2) δ 155.0, 154.6, 147.2, 146.9, 142.9, 141.9, 129.0, 128.8, 128.7, 128.6, 127.0, 126.8, 110.8, 
110.6, 82.9, 81.9, 80.5, 80.2, 54.9, 54.8, 46.8, 45.3, 43.0, 42.5, 37.8, 37.5, 28.5, 28.4 ; HRMS calcd for 
C18H25NO3NaS ([M+Na])+ 326.17321 found 326.1728 (0 ppm). 
General Procedure for preparation of the acetals 5  
To a dried pressure tube under an inert atmosphere, propargylic amine 2a (5 mol%) and {[Ru(Cp*)(CH3CN)3]PF6} (1 
mol%) were dissolved in methanol or ethanol (1 mL) followed by the addition of cinnamyl alcohol 1a (1.0 eq). The 
resulting solution was stirred at 100°C overnight. After concentration in vacuo, the crude mixture was purified by 
short column chromatography to afford the acetal 5 as product. 
(3,3-dimethoxypropyl)benzene 5a40 
 Prepared from cinnamyl alcohol 1a (50 mg, 0.239 mmol) and MeOH (1 mL). Filtration on silica gel using PE/Et2O 
(80:20) as eluent afforded compound 5a in 90% yield. 1H NMR (400 MHz, C6D6) δ 7.12-6.98 (m, 5H), 4.18 (t, J= 5.6 
Hz, 1H), 3.15 (s, 6H), 2.48 (t, J= 8.15 Hz, 2H), 1.74-1.69 (m, 2H).  
(6-methoxy-4-phenyl-1-tosylpiperidin-3-yl)methanol 6a 
BH3:DMS  (C= 1M, 0.3 mL) was slowly added to a solution containing 2-methoxy-5-methylene-4-phenyl-1-
tosylpiperidine 4a (30 mg, 0.08 mmol) in THF (0.5 mL) at 0°C and the resulting mixture was stirred for 2 hours. 
H2O2 (30%, 0.08 mL) and NaOH (3N, 0.08 mL) were sequentially added and the stirring was maintained for 3 h at 
room temperature. Extraction with H2O and CH2Cl2 x 3 followed by drying over sodium sulfate and concentration 
afforded a crude oil which was further purified by chromatography on silica gel using PE/Et2O (80:20) as eluent to 
afford compound 6a as yellow oil (24 mg, 76%) in a 75:19:6 stereoisomeric ratio (only the major compound is 
described), 1H NMR (400 MHz, C6D6) δ 7.74 (d, J= 8.1 Hz, 2H), 7.10-7.01 (m, 3H), 6.82-6.77 (m, 4H), 5.34 (t, J= 0.4 
Hz, 1H), 4.04 (d, J= 13.0 Hz, 1H), 3.44 (t, J= 10.5 Hz, 1H), 3.33 (td, J= 4.0, 13.0 Hz, 1H), 3.28-3.20 (m, 1H), 3.14-3.06 
(m, 2H), 2.95 (s, 3H), 1.92-1.82 (m, 1H), 1.87 (s, 3H), 1.79-1.68 (m, 2H); 13C NMR (100 MHz, C6D6), δ 141.5, 141.2, 
137.4, 128.1, 127.2, 126.2, 126.1, 125.2, 83.0, 56.0, 53.9, 40.6, 39.8, 35.1, 28.6, 19.7; HRMS calcd for 
C20H25NO4NaS [M+Na]+ 398.14020 found 398.1403 (0 ppm). 
General Procedure for the semi-hydrogenation of 3a. 
In a 20 mL reactor, containing 3-methylene-4-phenyl-1-tosyl-1,2,3,4-tetrahydropyridine 3a (30 mg, 0.09 mmol), 
THF (2 mL) was added followed by the addition of {Ru(Cp*)(CH3CN)3]PF6} and the additive (5 mol%). The autoclave 
was sealed, and was fast evacuated and filled with argon three times then ended with vacuum. The molecular 
hydrogen was introduced into the reactor at the indicated pressure. Then, the mixture was stirred at the 
mentioned temperature. After 15 hours the autoclave was cooled down to the room temperature and the 
hydrogen was then carefully released, the conversion was determined by GC, GC-MS and crude 1H NMR. 
Chromatography on silica gel using PE/Et2O (80:20) as eluent afforded compound 7a as yellow oil, as yellow oil, δ 
22.5 mg (75%), (only the cis compound is described) 1H NMR (400 MHz, C6D6) δ 7.68 (d, J= 7.8 Hz, 2H), 7.06-6.92 
(m, 4H), 6.79-6.75 (m, 3H), 6.60 (d, J= 6.9 Hz, 1H), 4.77 (dd, J= 5.0, 8.2 Hz, 1H), 3.39 (dd, J= 1.7, 10.9 Hz, 1H), 2.86 
(t, J= 5.0 Hz, 1H), 2.80 (t, J= 10.9 Hz, 1H), 1.88 (s, 3H), 1.76-1.68 (m, 1H), 0.29 (d, J= 6.7 Hz, 3H) ; 13C NMR (100 
MHz, CD2Cl2) δ 144.5, 140.8, 134.9, 130.2, 129.7, 128.0, 127.6, 126.9, 125.6, 110.0, 46.7, 42.6, 30.1, 20.0, 14.3 ; 
HRMS calcd for C19H21NO2SNaS ([M+Na])+  350.11907 found 350.119 (0 ppm). 
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